Provided by Tiger Trade Technology Pte. Ltd.

FOSUN PHARMA

16.080
+0.0900.56%
Volume:- -
Turnover:- -
Market Cap:42.76B
PE:10.85
High:16.080
Open:16.080
Low:16.080
Close:15.990
52wk High:28.232
52wk Low:14.505
Shares:2.66B
HK Float Shares:540.97M
Volume Ratio:- -
T/O Rate:- -
Dividend:0.46
Dividend Rate:2.83%
EPS(LYR):1.482
ROE:6.95%
ROA:1.40%
PB:0.75
PE(LYR):10.85
PS:0.86

Loading ...

Shanghai Fosun Pharma - Proposed to Distribute Cash Dividend of RMB0.39 for Each Ordinary Share

THOMSON REUTERS
·
Mar 25

Press Release: Fosun Pharma Announces 2025 Annual Results

Dow Jones
·
Mar 24

FOSUN PHARMA Subsidiaries to Expand Financing Through Leasing Agreements

Stock News
·
Mar 24

Fosun Pharma Reports 2025 Results: Dual Engines of Innovative Drugs and Globalization Drive High-Quality Growth

Stock News
·
Mar 24

Fosun Pharma (02196) Subsidiary Obtains NMPA Green Light for Sodium Thiosulfate Injection

Bulletin Express
·
Mar 20

FOSUN PHARMA Subsidiary Gains Approval for Phase I Trial of HLX18 in Solid Tumors

Stock News
·
Mar 20

FOSUN PHARMA's Sodium Thiosulfate Injection Receives Regulatory Approval

Stock News
·
Mar 20

Fosun Pharma (02196): Subsidiary MicroH Therapeutics Secures NMPA Green Light for Phase I Trial of LBP-ShC4 Live Biotherapeutic

Bulletin Express
·
Mar 16

FOSUN PHARMA's HLX07 Combined with Serplulimab Injection and Chemotherapy Cleared for Clinical Trial in Advanced Squamous Non-Small Cell Lung Cancer

Stock News
·
Mar 16

Fosun Pharmaceutical Gets Chinese Regulator's Nod for Clinical Trials of Blood Cancer Drug

MT Newswires Live
·
Mar 16

FOSUN PHARMA (02196) Subsidiary Secures NMPA Green Light for Phase I Trial of Next-Generation Bcl-2 Inhibitor FXS0683

Bulletin Express
·
Mar 13

FOSUN PHARMA Subsidiary Gains Approval for Clinical Trial of FXS0683 Tablets

Stock News
·
Mar 13

FOSUN PHARMA's Controlled Subsidiary Receives Clinical Trial Approval for Drug HLX316

Stock News
·
Mar 09

Fosun Pharma (02196) Sets 24 March 2026 Board Meeting to Review FY 2025 Results and Final Dividend Proposal

Bulletin Express
·
Mar 09

Fosun Pharmaceutical Gets Nod for Phase I Trial of Tumor Drug Candidate; Hong Kong Shares Up 5%

MT Newswires Live
·
Mar 06

Hong Kong Market Analysis: Strait Restrictions Eased, Focus on NPC Press Conference

Stock News
·
Mar 05

FOSUN PHARMA Subsidiary Receives Approval for Phase I Clinical Trial of HLX97 in Advanced/Metastatic Solid Tumors

Stock News
·
Mar 05

FOSUN PHARMA (02196) Announces February 2026 Monthly Return with Unchanged Share Capital

Bulletin Express
·
Mar 05